peripheral T cell repertoire that is tolerant toward both donor and host cells. Therefore, GVHD, one of the most important complications of allogeneic BMT, is not seen in mixed chimeras. 3. Mixed chimerism can be achieved through non-myeloablative regimens, which are generally less toxic than the myeloablative regimens necessary to induce full BM chimerism (this point will be discussed in detail in the next section).
How is mixed chimerism induced?
As explained above, once specific tolerance is established, the state of mixed chimerism is thought to be stable. The difficulty in establishing stable mixed chimerism lies in blocking the first attack of host peripheral T cells on donor bone marrow stem cells until "tolerized" T cells are renewed in the host thymus. Because host T cells play a dominant role in the rejection of allografts, several methods of deleting host T cells through the injection of various lymphocyte-deleting antibodies along with either total body irradiation or immunosuppressive drugs have been attempted (Tomita et al, 1996 . Nikolic et al, 2000 . These regimens enabled BM engraftment but were a burden on recipients and frequently made them susceptible to infection. The toxicity of the necessary conditioning regimens has precluded the use of this approach in clinical transplantation. Another method of inducing allogeneic tolerance involves the temporary inhibition of costimulatory interaction between APCs and T cells by injecting blocking antibodies. This method works because T cell activation without proper co-stimulation can induce a state of antigen-specific non-responsiveness ( Fig.1) .
Fig. 1. Activation of naïve T cells requires co-stimulation. Binding of the peptide/MHC
complex by the TCR and the CD4 or CD8 co-receptor transmits the first signal to the T cell. Activation of naïve T cells requires a second signal, namely, the ligation of B7 molecules (B7.1/B7.2) and CD28, which stimulates the clonal expansion of naïve T cells. Binding of CD40L by CD40 plays a central role effector function in the full differentiation of T cells. This ligation also activates APCs to express B7 molecules (left). Stimulation of CTLA4 with anti-CTLA4 Ab and/or Blocking CD40/CD40L by MR1 induces antigen-specific T cell tolerance (right).
Recently, Takeuchi et al. have shown that administration of MHC-mismatched donor bone marrow to mice receiving 3Gy TBI one day before BMT and a single injection of Hamster-anti-mouse CD40L monoclonal antibody (MR1, hybridoma) intraperitoneally (i.p.) with BMT permitted the induction of permanent mixed chimerism and tolerance without T cell depletion (Y. Takeuchi et al., 2004) . This regimen is quite simple and less toxic than the alternatives, because 3Gy TBI is nonlethal and does not require MHC matching. Therefore we have adopted this regimen for treatment of autoimmune disease in systemic lupus erythematosus (SLE) model mice ("BXSB"mice) and investigated the effect of induction of fully MHC-mismatched bone marrow mixed chimerism (E. Takeuchi & Y. Takeuchi, 2007) .
Treatment of autoimmune glomerulonephritis in BXSB lupus mice
3.1 BM mixed chimerism can be induced in BXSB mice BXSB mice spontaneously develop autoimmune disease with features similar to human SLE. The disease is associated with auto-antibodies to self-antigens (Ags) including d o u b l e s t r a n d ( d s ) D N A , s i n g l e s t r a n d ( s s ) D N A , a n t i -p l a t e l e t a n t i b o d i e s ( A b s ) a n d anti-erythrocyte Abs, with accompanying splenomegaly and lymphadenopathy. Immune complex-mediated nephropathy is the hallmark disease associated with the BXSB genotype. Histopathological changes are evident by 10 weeks of age, leading to end-stage renal disease and 70% mortality by 40 weeks of age. We sought to determine whether the simple regimen described above was also effective for the induction of long-term mixed chimerism in BXSB mice. Twenty million normal bone marrow cells from MHCmatched (B6/GFP: H-2 b ) or -mismatched (BALB/c: H-2 d ) donors were injected with 2.0mg MR1 (i.p.) to seven-week old BXSB mice (H-2 b ) that had received a nonlethal dose of 4Gy TBI one day prior to BMT. We increased the TBI dose for BXSB mice from 3 to 4Gy because BXSB mice are more resistant to engraftment than normal recipients are. This regimen allowed the induction of multi-lineage mixed chimerism in 70-90% of host BXSB mice.
As shown in Table 1 and Fig.2 , long-term stable chimerism was observed in MHCmismatched chimeric mice. No clinical signs of GVHD were seen during the observation period. To confirm the establishment of donor-specific tolerance, chimeric BXSB mice also received skin grafts from a BM donor and a third party (C3H/HeN, H-2 k ) one day after BMT. All chimeric BXSB mice accepted the donor skin, but rejected the third-party skin grafts within 20 days (Fig.3) , indicating that chimeric BXSB mice acquired donor-specific tolerance without immune-deficiencies (E. Takeuchi, 2011) .
www.intechopen.com These results indicate that, with regard to reciprocal tolerant between donor and host, T cells in stable mixed chimeric mice do not reject additional tissue grafts transplanted from the same donor. In lupus patients who suffer from renal disorders, and who are treated by means of kidney transplantation, the induction of specific immunologic tolerance to donor antigens would prevent both chronic graft rejection and the side effects associated with chronic, nonspecific immunosuppressive therapy.
Induction of mixed chimerism suppressed lupus nephritis in BXSB mice
Even when transplanted kidneys are engrafted stably, when pre-existing lupus goes untreated, renal disorder will eventually recur. It is also known, however, that the induction of mixed chimerism reverses the autoimmune state. To evaluate the effect of inducing MHCmatched or MHC-mismatched mixed chimerism, individual kidneys were harvested from experimental mice and tissue sections were stained with periodic acid-Schiff (PAS) for histopathologic examination. None of the donor mouse strains were prone to autoimmune disease ( Fig.4A) . In both the fully MHC-matched and the fully MHC-mismatched chimeric mice groups, lupus glomerulonephritis was significantly ameliorated compared with that in untreated BXSB mice, as revealed by pathological analysis conducted more than 40 weeks after BMT (Figs.4D and E). 
Hypothesis
We and several other groups have shown that the induction of bone marrow mixed chimerism is an effective treatment for and/or means of prevention against the development of autoimmune disease. Previous studies have debated the mechanisms that may be responsible for the reversal of the autoimmune state in BM chimerism, but the mechanism of the exclusion of self-reactive lymphocytes has not yet been conclusively identified. Preceding studies have argued about the mechanisms underlying the reversal of the autoimmune state in BM chimerism. In several studies which reversed destructive autoimmune type І diabetes (NOD mice with induced mixed chimerism), the suppression of autoimmune disease was attributed to reciprocal clonal deletion or to anergy induction of T lymphocytes of recipient and donor origin (Mathieu et al., 1997 . Nikolic et al., 2004 . Other mechanisms have also been proposed, including induction of peripheral anergy, a change in the Th1/Th2 profile, correction of abnormal secretion of cytokines and positive selection of regulatory T cells in the thymus. Among proposed hypotheses, we have focused on the role of cognate TCR/MHC interactions in the pathogenesis of autoimmune disease in BXSB mice (E. Takeuchi et al., 2011) 
The induction of MHC-mismatched chimerism does not suppress anti-DNA Abs
During the development of their lupus-like autoimmune disease, BXSB mice are known to produce auto-antibodies to self-antigens including dsDNA. We measured serum anti-dsDNA antibody (anti-DNA Ab) levels by means of ELISA to evaluate whether autoreactive Abs were eliminated by the induction of mixed chimerism. Actually, the anti-DNA Ab levels in both MHC-matched and MHC-mismatched chimeric mice were lower than those in untreated or irradiated BXSB mice. Meanwhile, anti-DNA Ab levels in fully MHCmatched mixed chimeric mice (GFP/B6 BMT) were not statistically different from those in normal control B6 mice, but those in fully MHC-mismatched mixed chimeric mice (BALB/c BMT) were significantly higher than those in normal controls. This tendency was even more pronounced when anti-DNA IgM levels in the above groups were compared. There were no significant differences in anti-DNA IgM levels between MHC-mismatched chimeric mice and untreated or TBI+MR1 mice, even though total anti-DNA levels were much lower in chimeric mice than in other groups. These data indicated that anti-DNA Ab producing cells were still present in the BXSB chimeric mice, though they stopped switching iso-types from IgM to IgG in MHCmismatched chimera. Only in MHC-matched chimeric mice could the expansion of anti-DNA Ab production be suppressed down to a normal level; the induction of fully MHCmismatched chimerism did not completely suppress or eliminate anti-DNA-producing B cells.
Selective suppression of auto-reactive antibodies in chimeric mice
In order to distinguish the contributions of donor-type and host-type B cells to anti-dsDNA antibody production, we determined IgM allotypes [IgMa: BALB/c (donor), IgMb: BXSB (host)] in the serum of fully MHC-mismatched (BALB/c→BXSB) chimeric mice 20 weeks after BMT. At this point, the percentage of allogeneic donor B cells in the chimeric mice was 51.011.8%, indicating that allogeneic donor and host B cells had contributed equally to the immune response. Surprisingly, however, we found that the majority of the anti-DNA IgM was IgMa (allogeneic donor-type), whereas IgMb (host-type) anti-DNA antibody production was suppressed (Fig. 5A) . The majority of the total serum IgM, on the other hand, was host-type IgMb (Fig. 5B) , suggesting that the production of "normal" serum Ig is dependent on host MHC-restricted T cells. Total serum IgM levels in fully MHC-mismatched chimeric mice were not significantly Interestingly, however, our results indicated the possibility that not only "proper" activation against foreign antigens, but also suppression of auto-reactive antibody production were regulated through TCR/MHC cognate interactions.
Do T cells survey auto-reactive antibody production?
Based on these data, we drew the following conclusions: 1. Allogeneic BM chimerism ameliorates autoimmune disease, but fully MHC-mismatched chimerism fails to suppress the production of anti-DNA antibodies. 2. In MHC-mismatched mixed chimeras, anti-DNA antibodies are produced by donor-type B cells rather than host-type B cells. 3. In MHC-mismatched chimera, TCRs are restricted to host-type MHC. Accordingly, T cells can recognize only host B cells but not donor B cells. To tie theses conclusions together, we propose a possible T cell surveillance system of mixed chimerism, as depicted in Fig.6 . T cell precursors derived from BM differentiate to mature T cells in the host thymus. Through a process known as positive selection, all T cell populations can interact with self-MHC with proper affinity. Since these processes are performed by MHC molecules expressed on thymic epithelial cells, the TCR repertoire in mixed chimera is restricted to host MHC. We and others speculate that under genetically normal conditions, T cellmediated trimming of autoantibody production may occur through cognate interactions between TCR and MHC+peptide presented on B cells (Rathmell et al., 1995 , Shinohara et al., 1997 . In the case of the BXSB mouse, it is known that T cells have certain defects which might play an important role in the pathogenesis of autoimmunity (Wofsy, 1986) . We also speculate that the pivotal defect of BXSB may be a genetic defect in this surveillance function of T cells (Fig.6A ). In the case of fully MHC-matched chimerism, T cells derived from donor BM can take this place of defective host T cells. Auto-reactive B cells derived from both donor and host BM can be regulated or trimmed by donor T cells through TCR/MHC interactions (Fig.6B) . In MHC-mismatched chimerism, immature T cells are positively selected on the basis of their weak reactivity with self-peptides presented exclusively on H-2 b MHC molecules, since thymic epithelial cells express only host MHC. Therefore, in the periphery, all T cells recognize antigens presented by APCs on H-2 b MHC molecules (BXSB: host type MHC). Yet, B cells expressing H-2 d MHC (BALB/c: donor type MHC) are still generated from donor BM stem cells as this process is genetically determined. T cells developing in the BXSB thymus should be incapable of cognate interactions with these "wrong" MHC molecules expressed on donor B cells. We speculate that the failure of cognate interaction with T cells might be the reason why auto-reactive antibody levels rose in MHC fully-mismatched chimeric mice (Fig.6C ). The present study did not address the question of how anti-self B cells were initially triggered. We also induced fully MHC-mismatched BM chimerism in normal B6 mice (BALB/c→B6) as opposed to lupus BXSB mice. The anti-DNA Ab levels seen in BALB/c→B6 chimeric mice were slightly higher than those in normal B6 mice, but, much lower than those seen in BALB/c→BXSB chimeric mice (data not shown). This means that the induction of fully MHC-mismatched chimerism in normal mice may carry a risk of autoantibody production, though uncertain factors in host BXSB mice drives a nonphysiological priming of B cells.
BMT from haplo-identical donor effectively suppressed auto-antibody production
If there is indeed a host-type MHC restriction in the suppression of auto-reactive antibody production, BMT from a donor with partially identical MHC that is sufficient to maintain cognate interaction should be equally as effective as BMT from a fully MHC-matched GFP/B6 mouse. To test this hypothesis, BM cells taken from BALB/c (H-2 d )  GFP/B6 (H-2 b ) F1 mice with haplo-identical MHC (H-2 b/d ) were transplanted to BXSB (H-2 b ) mice.
In this case, all B cells, even those differentiated from donor BM, contained at least one H-2 b allele. As shown in Figs.4F and L, lupus glomerulonephritis in F1 chimeric mice was alleviated to a degree comparable to that seen in MHC-matched GFP/B6 chimeric mice. Serum anti-DNA Ab in F1 chimeric mouse group was decreased to level comparable to that seen in fully MHC-matched GFP/B6 chimeric mice (data not shown).
The survival rates in both the GFP/B6 chimeric mouse group and the F1 chimeric mouse group, which were higher than that in the BALB/c chimeric mouse group, indicated that BMT from F1 mice is also effective as a treatment for lupus-like disease in BXSB mice (B6 
Clinical application and unknown risks of mixed chimerism
This paper has demonstrated that the maintenance of TCR/MHC interaction with all B cells is important in regulating auto-reactive Ab production. However, we and several other groups have reported that the induction of fully MHC-mismatched chimerism is certainly effective as a treatment for autoimmunity. How does the induction of fully MHCmismatched mixed chimerism suppress autoimmune disease? One answer to this question is demonstrated by the results of an immunohistochemical experiment in which we staind for several isotypes of immunoglobulin. As depicted in Table 2 , linear staining patterns with IgG and/or IgM were definitely observed on the glomeruli of kidney sections taken from MHC-mismatched chimeric mice; the same sections were negative for C3 depositions, however. Linear staining with both IgG and C3 was observed on the glomeruli taken from untreated mice. However, the potential disadvantage of this process is that some of the antibodies could be auto-reactive.
To test this hypothesis, we induced an auto-cross-reactive antibody (Ab) by introducing a foreign antigen with a homolog to an auto-antigen into a BXSB lupus mouse strain of mixed chimerism with several combinations of donor BM. The titer of auto-cross reactive foreign Ab plateaued at low levels in normal mice and MHC-matched/haplo-identical chimeric mice, but rose higher in BXSB and fully MHC-mismatched chimeric mice (unpublished data). These results indicate that the induction of fully MHC-mismatched chimerism may carry a risk of secondary auto-antibody production. Under normal conditions, these auto-reactive B cells may be anergic. In lupus patients, however, non-physiological factors may prime auto-reactive B cells. For example, it has been reported that circulating B cell activating factor (BAFF) is elevated in the serum of human patients with lupus, and that the overexpression of BAFF in mice promotes TLR-induced production of auto-antibodies through a T cell independent process (Groom et al., 2007) . Under autoimmune conditions, normal B cell may have the potential to run off the rails. The maintenance of TCR/MHC interaction may be a "rein" by which immune-response is controlled in chimeras. Because several mechanisms have been suggested as drivers of autoimmune disease, further study is necessary to identify each mechanism's role. Nevertheless, our results showing the specific suppression of auto-reactive antibody production suggest the existence of a surveillance system that trims auto-reactive B cells after priming. The reconstitution of this surveillance system through the induction of BM mixed chimerism can be an effective treatment for lupus disease. Moreover, the induction of BM mixed chimerism with haploidentical donor BM, which maintains cognate T/B interaction with both donor and host cells, can be equally effective as fully MHC-matched donor BM. These results may support the clinical application of BMT as a treatment for lupus disease.
Conclusions
Induction of BM mixed chimerism can be useful for treatment of refractory lupus glomerulonephritis. Elucidation the mechanism through which mixed chimerism reverses the autoimmune state is necessary for clinical application.
In this paper, we suggested the existence of T cell surveillance system through TCR/MHC interaction. Through TCR/MHC interaction, T cell-mediated trimming of auto-antibody production may occur under normal condition. The induction of bone marrow mixed chimerism may reverse the auto-immune state through reconstruction of the T cell
